

Aripiprazole Market Forecast to 2034 – For Business Leaders, Analysts, and Strategic Teams

The Business Research Company's Aripiprazole Market Forecast to 2034 – For Business Leaders, Analysts, and Strategic Teams

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- <u>The Business</u> <u>Research Company</u>'s Latest Report



Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

What Are The Anticipated Growth Rates And Size For The Aripiprazole Global Market? The aripiprazole market has predominantly shown strong growth in recent years, escalating from

٢٢

It will grow to \$10.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. "

> The Business Research Company

\$7.04 billion in 2024 to an estimated \$7.65 billion in 2025, a compound annual growth rate CAGR of 8.6%. Factors contributing to this historic growth include the increasing prevalence of schizophrenia and bipolar disorders, growing awareness of mental health, expanded usage of aripiprazole, an increasing geriatric population, and rising healthcare expenditure.

What Does The Future Hold For The Aripiprazole Market?

Looking forward, the aripiprazole market's growth trajectory shows no signs of slowing. By 2029, the market is expected to surge to reach \$10.53 billion with a CAGR of 8.3%. This significant growth can be attributed to the increasing prevalence of depression and anxiety disorders, a growing focus on personalized medicine, increasing acceptance of generic aripiprazole, rising investment in psychiatric drug research, and the expansion of telepsychiatry and digital health platforms.

Get Your Free Sample Market Report: <u>https://www.thebusinessresearchcompany.com/sample.aspx?id=24150&type=smp</u>

What Is Driving The Growth Of The Aripiprazole Market?

One major growth driver for the increasing aripiprazole market is the rising prevalence of psychiatric disorders. These mental health conditions can greatly impact the individual's thoughts, emotions, behavior, and overall functioning. Due to factors such as chronic stress, social isolation, and modern lifestyle pressures, more people are experiencing psychiatric disorders, causing a steady rise in their prevalence.

Moreover, the growth of the healthcare expenditure is also a key driver for the aripiprazole market. Growing investment in long-term mental health treatments, access to advanced mental health services, and a consistent supply of medication all contribute to an increased usage of aripiprazole.

For instance, according to the Centers for Medicare and Medicaid Services CMS, a US-based federal agency, the national health expenditures NHE grew by 7.5% to \$4.9 trillion in 2023, which is 17.6% of the gross domestic product GDP. Between the period of 2023 and 2032, these average national health expenditures NHE are expected to grow at an annual rate of 5.6%, resulting in an increase of health spending from 17.3% of GDP in 2022 to 19.7% in 2032.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/aripiprazole-global-market-report

Who Are The Major Players In The Aripiprazole Market?

The aripiprazole market is characterized by the presence of several leading companies, including Novartis AG, Teva Pharmaceutical Industries Ltd., Hetero Drugs, Sun Pharmaceutical Industries Ltd., Cipla Limited, Zydus Lifesciences, Neuland Laboratories Ltd., Ipca Laboratories Limited, Jubilant Pharmova, MSN Laboratories Pvt. Ltd., Harman Finochem Ltd., SMS Pharmaceuticals, Erregierre S.p.A., Tiefenbacher API + Ingredients GmbH & Co. KG, Alkem Laboratories Ltd., Suraj Laboratories Pvt. Ltd, Octavius Pharma Pvt. Ltd., Tooba Pharmaceuticals Private Limited, Senores Pharmaceuticals Pvt. Ltd., and Gonane Pharma.

What Are The Emerging Trends In The Aripiprazole Market?

Companies operating in this market are focusing on developing innovative products and receiving approvals for products like long-acting injectable formulations. This drive for innovation enables them to expand their therapeutic applications and maintain competitiveness even after patent expiration. For instance, Otsuka Pharmaceutical Co. Ltd., along with Lundbeck, received FDA approval in September 2022 for their two-month, ready-to-use aripiprazole injection. This represents a major advancement in the treatment of schizophrenia and bipolar I disorder in adults.

How Is The Aripiprazole Market Segmented?

The aripiprazole market is segmented by:

1 By Indication: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Autism Spectrum Disorder

2 By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

3 By Dosage Form: Oral Tablets, Oral Solution, Injectable

4 By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Further analysis of these segments reveals:

1 By Schizophrenia: Acute Schizophrenia, Maintenance Treatment for Schizophrenia

2 By Bipolar Disorder: Bipolar I Disorder, Bipolar II Disorder, Bipolar Depression

3 By Major Depressive Disorder: Treatment-Resistant Depression, Acute Major Depressive Disorder

4 By Autism Spectrum Disorder: Irritability Associated with Autism, Aggressive Behavior in Autism.

How Is The Distribution Of The Aripiprazole Market By Region?

North America was the largest region for the aripiprazole market in 2024. However, the fastestgrowing region going forward is expected to be Asia-Pacific. Other regions covered in this report include Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Autism Spectrum Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorders-treatmentglobal-market-report

Bipolar Disorder Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-globalmarket-report

Insulated Gate Bipolar Transistor (IGBT) Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulated-gate-bipolar-transistor-igbtglobal-market-report

About The Business Research Company

Learn More About The Business Research Company. With its 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get all the information you need to stay ahead in the game.

Contact us at: The Business Research Company: <u>https://www.thebusinessresearchcompany.com/</u> Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708

Follow us on:

Email us at info@tbrc.info

LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> YouTube: <u>https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ</u> Global Market Model: <u>https://www.thebusinessresearchcompany.com/global-market-model</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: LinkedIn Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/822589760

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.